Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Other Gross PP&E Adjustments (2019 - 2025)

Historic Other Gross PP&E Adjustments for Myriad Genetics (MYGN) over the last 9 years, with Q3 2025 value amounting to $144.1 million.

  • Myriad Genetics' Other Gross PP&E Adjustments fell 1779.81% to $144.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.1 million, marking a year-over-year decrease of 1779.81%. This contributed to the annual value of $165.4 million for FY2024, which is 400.46% down from last year.
  • Per Myriad Genetics' latest filing, its Other Gross PP&E Adjustments stood at $144.1 million for Q3 2025, which was down 1779.81% from $141.2 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Other Gross PP&E Adjustments peaked at $233.0 million during Q3 2023, and registered a low of $59.5 million during Q2 2021.
  • Over the past 5 years, Myriad Genetics' median Other Gross PP&E Adjustments value was $144.1 million (recorded in 2025), while the average stood at $133.4 million.
  • Per our database at Business Quant, Myriad Genetics' Other Gross PP&E Adjustments soared by 39011.98% in 2021 and then crashed by 2476.39% in 2024.
  • Quarter analysis of 5 years shows Myriad Genetics' Other Gross PP&E Adjustments stood at $64.1 million in 2021, then surged by 32.76% to $85.1 million in 2022, then skyrocketed by 102.47% to $172.3 million in 2023, then fell by 4.0% to $165.4 million in 2024, then dropped by 12.88% to $144.1 million in 2025.
  • Its last three reported values are $144.1 million in Q3 2025, $141.2 million for Q2 2025, and $144.1 million during Q1 2025.